The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Safety and tolerability of caspofungin acetate in the treatment of fungal infections
Abstract
Caspofungin acetate is the first member of the novel echinocandin class of antifungal drugs to be marketed in the United States. It has recently been approved for use in patients with invasive aspergillosis who are refractory to or intolerant of conventional therapy. Accordingly, its safety profile is particularly important to review. The safety and tolerability of caspofungin have been examined in 623 persons, including 295 patients who received >/= 50 mg/day for at least one week in clinical studies. In the 263 patients, given caspofungin in randomized double-blind active-control trials to date, there have been no serious clinical or laboratory drug-related adverse events; caspofungin was discontinued in only 2% of these patients because of drug-related adverse experiences. Caspofungin may have potentially important drug interactions with cyclosporine and tacrolimus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Caspofungin has been shown to be as effective as both amphotericin B deoxycholate and fluconazole when used as therapy for oropharyngeal and esophageal candidiasis [57][58][59][60].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [57]
Citations
Cites
Discovery of Novel Antifungal (1,3)-β- d -Glucan Synthase Inhibitors
Onishi, J. C., Meinz, M., Thompson, J. R., Curotto, J. E., Dreikorn, S., Rosenbach, M. J., Douglas, C. M., Abruzzo, G. K., Flattery, A. M., Kong, L., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.368-377.2000 · Cited by 329
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Current and future antifungal therapy: new targets for antifungal agents
Andriole, V. T. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.151 · Cited by 191
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
Hajdu, R., Thompson, R. K., Sundelof, J. G., PELAK, B. A., Bouffard, F. A., Dropinski, J. F., & Kropp, H. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2339 · Cited by 165
Metabolites of Caspofungin Acetate, a Potent Antifungal Agent, in Human Plasma and Urine
Balani, S. K., Xu, X., Arison, B. H., da Silva, M. V. M., Gries, A., Deluna, F. A., Cui, D., Kari, P. H., Ly, T., Hop, C. E. C. A., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15072-6 · Cited by 104
Research works printed but not linked: 6
- SableCA VillaneuvaA ArathoonE et al.A randomized double‐blind multicenter trial of MK‐0991 (L‐743872) versus amphotericin B (AMB) in the treatment ofCandidaesophagitis in adults.Presented at the 37th Interscience Conference on Antimicrobial Agents Chemotherapy.Toronto Ontario Canada October 1997: LB‐33.
- Stone JS, 1998, Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Xu X, 1998, Disposition of MK‐0991, a potent antifungal agent, in rats with acute renal failure, Pharm Sci, 1, 463
- Stone JA, 2000, Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;
- Stone JA, 2000, Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;
- Stone J, 2001, Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy;
Cited by
Sorted by citations
Items 101–147 of 147
Actualización en terapia antifúngica: nuevos fármacos e indicaciones
Fortün, J. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70042-8 · Cited by 9
Morrissey, C. O., & Slavin, M. A. (2006) · Medical Mycology · doi:10.1080/13693780600826699 · Cited by 8
A Review on production of echinocandins by Aspergillus sp
Goswami, S., Rani, A., Priyadarshini, R., Bhunia, B., & Mandal, T. (2013) · Journal Of Biochemical Technology · Cited by 8
Bergmann, T. K., Isbel, N. M., Barraclough, K. A., Campbell, S. B., McWhinney, B. C., & Staatz, C. E. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-013-0162-1 · Cited by 8
Echinocandin use in lung transplant recipients
Jishi, Y. A., Rotstein, C., Kumar, D., Humar, A., Singer, L. G., Keshavjee, S. H., & Husain, S. (2018) · Clinical Transplantation · doi:10.1111/ctr.13437 · Cited by 8
Cheng, Q., Wu, Y., Yao, Z., Ouyang, M., Zou, S., Shi, X., Zhao, Y., & Sun, M. (2024) · Thrombosis Journal · doi:10.1186/s12959-024-00641-4 · Cited by 7
Pressiat, C., Aït‐Ammar, N., Daniel, M., Lesne-Hulin, A., Botterel, F., & Levesque, É. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01187-21 · Cited by 7
Infección fúngica invasora en el trasplante de órgano sólido
Gavaldà, J., Meije, Y., Len, Ó., & Pahissa, A. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.09.004 · Cited by 7
COMPARISON OF CASPOFUNGIN AND AMPHOTERICIN B FOR INVASIVE CANDIDIASIS
Ora, J., Etts, R. O. B., Otstein, C. O. R., Rnaldo, A., Olombo, L. O. C., Hompson, L. U. T., Upinacci, R. O. L., Artsonis, I. K., Erfect, J. O. P., & Roup, S. T. G. (2002) · Cited by 7
Yang, C., Yin, X., Chen, W., Sang, L., Liu, D., Zhang, R., Chen, S.-B., Zhang, J., Pan, J., Xv, Y.-H., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1191 · Cited by 6
Tálas, L., Szigeti, Z. M., Bánfalvi, G., & Szemán-Nagy, G. (2019) · AMB Express · doi:10.1186/s13568-019-0769-6 · Cited by 6
Caspofungin Effects on Electrocardiogram of Mice: An Evaluation of Cardiac Safety
de Paula, D. C. C., Leite, E. A., Araújo, C. M., Branquinho, R. T., Guimarães, H. N., & Grabe‐Guimarães, A. (2020) · Cardiovascular Toxicology · doi:10.1007/s12012-020-09599-x · Cited by 6
Echinocandins: A promising new antifungal group
Randhawa, G. K., & Sharma, G. (2004) · Bioline International (Bioline International) · Cited by 6
Zhang, Y., Shen, B., Li, Y., Zong, H., Zhang, X., Cao, X., Liu, F., & Li, Y. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241243165 · Cited by 6
Wiederhold, N. P., & Herrera, L. A. (2012) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s8016 · Cited by 6
Anttila, V., Salonen, J. H., Ylipalosaari, P., Koivula, I., Riikonen, P. V., & NIKOSKELAINEN, J. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01709.x · Cited by 4
Echinocandin-induced eosinophilia: a case report
Chua, N. G. S., Zhou, Y. P., Lingegowda, P. B., Kwa, A. L., & Lee, W. (2014) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2014.938692 · Cited by 4
Serial Aspergillus Antigen Monitoring in Pediatric Bone Marrow Transplant Patients
Baker, C. (2006) · Journal of Pediatric Oncology Nursing · doi:10.1177/1043454206293260 · Cited by 4
Groll, A. H., Schrey, D., & Walsh, T. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_6 · Cited by 4
Steinbach, W. J., & Dvorak, C. C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00295-6 · Cited by 4
Pióro, A., Latos, M., Urlik, M., Stącel, T., Gawęda, M., Pandel, A., Przybyłowski, P., Knapik, P., & Ochman, M. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.02.015 · Cited by 3
Caspofungin: the first licensed antifungal drug of the novel echinocandin class
DiNubile, M. J., Motyl, M. R., & Sable, C. A. (2004) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2004.05.001 · Cited by 3
Invasive Aspergillosis in Solid Organ Transplant Recipients
Sun, H., Muñóz, P., Bouza, E., & Singh, N. (2014) · ASM Press eBooks · doi:10.1128/9781555815523.ch38 · Cited by 2
Mold Infections in Solid Organ Transplant Recipients
Muñóz, P., Giannella, M., Vena, A., & Bouza, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-28797-3_40 · Cited by 2
Evidence-based approach to challenging issues in the management of invasive aspergillosis
Singh, N. (2009) · Medical Mycology · doi:10.1080/13693780802552598 · Cited by 2
▼Caspofungin and ▼voriconazole for fungal infections
(2004) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2004.4215 · Cited by 2
Myasthenia gravis and community-acquired pneumonia: therapeutic challenges
Chen, X., Ding, J., Zhang, J., Dai, H., & Yu, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1695526 · Cited by 1
Invasive periodic multivisceral aspergillosis in HIV-infected patient with normal CD4+ cell count
Hasseine, L., Roger, P., Novellas, S., Salvador, F. D., Dunyach‐Remy, C., Bertout, S., & Gari-Toussaint, M. (2011) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2011.03.005 · Cited by 1
Keiler, S. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-16 · Cited by 1
Invasive fungal infections in children: advances and perspectives
Groll, A. H., Köhler, J. R., & Walsh, T. J. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8099-1_16 · Cited by 1
Les échinocandines : mise au point
Pilmis, B., Lopes, A., Lortholary, O., & Charlier, C. (2013) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2013.02.005 · Cited by 2
Neoh, C. F., Kong, D. C. M., Slavin, M. A., & Chen, S. C.-A. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0085-y
Koldehoff, M. (2010) · Springer eBooks · doi:10.1007/978-3-642-12173-9_12
Antifungal Management in Risk Groups
Costa, S. F., & Alexander, B. D. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-25
Recent Advances in the Therapy Against Invasive Aspergillosis
Gonzalez, C. E. (2004) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8993-2_31
Formación Médica Continuada: infección fúngica invasora Aspergilosis. Formas clínicas y tratamiento
Fortün, J., Meije, Y., Fresco, G., & Moreno, S. (2016)
Aspergillosis in Solid Organ Transplantation
Singha, N. M. (2013)
Perlin, D. S., & Hope, W. W. (2009) · Springer eBooks · doi:10.1007/978-90-481-2408-4_16
Steinbach, W. J., & Dvorak, C. C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7020-3468-8.50299-6
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00515-5
(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53272-5.50007-8
Echinocandins for Prevention and Treatment of Invasive Fungal Infections
Johnson, M. D., & Mohr, J. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-14
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00672-7
Groll, A. H., Kolve, H., & Walsh, T. J. (2004) · Side effects of drugs annual · doi:10.1016/s0378-6080(04)80034-5
Wichmann, D., Hoenigl, M., Koehler, P. A., Koenig, C., Lund, F., Mang, S., Strauß, R., Weigand, M. A., Hohmann, C., Kurzai, O., et al. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01265-w
Ara, T. (2025) · Japanese Journal of Transplantation and Cellular Therapy · doi:10.7889/tct-25-001
Bubna, A. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-3791-4_20
Metadata
- Authors
- Sable, C. A., Nguyen, B. T., Chodakewitz, J. A., & DiNubile, M. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Transplant Infectious Disease
- Publisher
- Wiley
- Published
- 2002-03
- Volume
- 4
- Issue
- 1
- Pages
- 25-30
- ISSN
- 1398-2273 (ISSN-L)
- 1399-3062
- OpenAlex
- W2041457471
- Cited by
- 148
- References
- 5
- Citations by year
- 2025: 4 · 2024: 2 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 7 · 2013: 4 · 2012: 7
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplant Infectious Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- caspofungin acetate, echinocandins, antifungal agents, invasive aspergillosis, drug safety, tolerability, adverse drug reactions, refractory fungal infection
- MeSH terms
- Caspofungin, Anti-Bacterial Agents, Antifungal Agents, Aspergillosis, Candidiasis, Double-Blind Method, Drug Tolerance, Fever, Headache, Humans, Mycoses, Peptides, Peptides, Cyclic, Phlebitis, Retrospective Studies, Randomized Controlled Trials as Topic, Immunocompromised Host, Drug Approval, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
